The latest market price reference for lenvatinib/lenvatinib in 2026

Lenvatinib/lenvatinib (Lenvatinib), as a multi-target tyrosine kinase inhibitor, has been widely used in the treatment of various solid tumors in recent years. Its market price and accessibility have always been the focus of patients. Judging from the current domestic drug use environment, lenvatinib has been officially launched in China and has been included in the national medical insurance system, which means that patients with renal cell carcinoma, hepatocellular carcinoma, etc. can obtain the drug through regular hospital channels, which can reduce the economic burden to a certain extent. The most common domestic specifications are 4 mg × 30 tablets, and the market retail price is roughly around 3,000 yuan. The actual amount paid by an individual needs to be comprehensively judged based on local medical insurance reimbursement ratios, hospital implementation policies and other factors. Therefore, more accurate information is usually based on the hospital pharmacy.

In terms of market, the price structure of lenvatinib shows obvious regional differences. The pricing of original drugs in different countries and regions is affected by multiple factors such as drug negotiation mechanisms, tax policies, and exchange rate fluctuations. In some markets, the price of the original research lenvatinib when converted into RMB is lower than that in China, about RMB 2,000. This is also one of the important reasons why some patients pay attention to the channel. It needs to be emphasized that the active ingredients and quality standards of original drugs are consistent whether they are domestic or foreign, and the price difference does not represent a difference in efficacy.

At the same time, generic drugs of lenvatinib are gradually entering patients' horizons. Currently, the more common sources include Laos and Bangladesh. As long as these generic drugs are legal and compliant, their main ingredients are consistent with the original drugs. The price range is usually between RMB 400 and RMB 900, making them attractive to patients with greater financial pressure. However, from the perspective of medicine and pharmaceutical management, when choosing generic drugs, patients should pay more attention to whether the source of the drug is regular and whether the production standards are reliable, rather than relying on price as the only basis for judgment.

Reference materials:https://www.lenvima.com/